argenx SE (ARGX) has announced the approval of VYVDURA by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
VYVDURA is the first and only neonatal Fc receptor (FcRn) blocker approved for CIDP, designed for once-weekly subcutaneous injections lasting 30 to 90 seconds. These injections can be conveniently self-administered by patients at home.
CIDP is a rare and progressively debilitating neuromuscular disorder of the peripheral nervous system, characterized by severe mobility and sensory challenges. Patients often experience difficulties such as trouble standing from a seated position, pain, fatigue, and frequent tripping or falling.
In addition to CIDP, VYVDURA is also approved in Japan for at-home self-injection for generalized myasthenia gravis, making the country the first globally to offer access to the argenx VYVGART and VYVDURA portfolio across three different indications.
The material has been provided by InstaForex Company - www.instaforex.com
VYVDURA is the first and only neonatal Fc receptor (FcRn) blocker approved for CIDP, designed for once-weekly subcutaneous injections lasting 30 to 90 seconds. These injections can be conveniently self-administered by patients at home.
CIDP is a rare and progressively debilitating neuromuscular disorder of the peripheral nervous system, characterized by severe mobility and sensory challenges. Patients often experience difficulties such as trouble standing from a seated position, pain, fatigue, and frequent tripping or falling.
In addition to CIDP, VYVDURA is also approved in Japan for at-home self-injection for generalized myasthenia gravis, making the country the first globally to offer access to the argenx VYVGART and VYVDURA portfolio across three different indications.
The material has been provided by InstaForex Company - www.instaforex.com